Glial role in oxaliplatin-induced neuropathic pain

  title={Glial role in oxaliplatin-induced neuropathic pain},
  author={Lorenzo Di Cesare Mannelli and Alessandra Pacini and Laura Micheli and Alessia Tani and Matteo Zanardelli and Carla Ghelardini},
  journal={Experimental Neurology},

The Role of Satellite Glial Cells, Astrocytes, and Microglia in Oxaliplatin-Induced Neuropathic Pain

By reviewing 23 studies that conducted in vivo experiments in rodents, the change of satellite glial cells, astrocytes, and microglia activation in the dorsal root ganglia, spinal cord, and the brain of oxaliplatin-induced neuropathic pain animals is discussed and suggests that targeting the glia may be an effective therapeutic option.

Niclosamide Inhibits Oxaliplatin Neurotoxicity while Improving Colorectal Cancer Therapeutic Response

Results indicate that niclosamide exerts its neuroprotection both in vitro and in vivo by limiting oxaliplatin-induced oxidative stress and neuroinflammation.

Therapeutic Agents for Oxaliplatin-Induced Peripheral Neuropathy; Experimental and Clinical Evidence

The basic and clinical evidence for the therapeutic effects of oxaliplatin is summarized and it is important to activate translational research in order to translate basic research into clinical research.

Management of Oxaliplatin-Induced Peripheral Sensory Neuropathy

It can be concluded that prevention and treatment of OIPN still remains an important and unmet clinical need, and dose and schedule modification of OHP-based chemotherapy is currently the most effective approach to limit the severity of OipN.

Exenatide Facilitates Recovery from Oxaliplatin-Induced Peripheral Neuropathy in Rats

Exenatide may be useful for treating peripheral neuropathy induced by oxaliplatin in colorectal cancer patients with type 2 diabetes, and facilitated recovery from the oxali platin-induced neuropathy with reparation of axonal degeneration.

Antineuropathic Profile of N-Palmitoylethanolamine in a Rat Model of Oxaliplatin-Induced Neurotoxicity

Ex vivo histological and molecular analysis of dorsal root ganglia, peripheral nerves and spinal cord highlighted neuroprotective effects and glia-activation prevention induced by PEA repeated administration, suggesting the usefulness of PEA in chemotherapy-induced neuropathy.

Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy

This review focusses on the commonly used antineoplastic substances oxaliplatin, cisPlatin, vincristine, docetaxel, and paclitaxel which interfere with the cancer cell cycle—leading to cell death and tumor degradation—and cause severe acute and chronic peripheral neuropathies.

Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment

The most important mechanism involved in acute OIPN is the alteration of voltage-gated Na + channels, and nuclear DNA damage in chronic OIPn.

Rosmarinic Acid Mitigates Mitochondrial Dysfunction and Spinal Glial Activation in Oxaliplatin-induced Peripheral Neuropathy

The therapeutic activity of RA is demonstrated against the oxaliplatin-induced mitochondrial dysfunction and neuroinflammation and thus, suggest its potential for the management of OIPN.

The α9α10 nicotinic receptor antagonist α-conotoxin RgIA prevents neuropathic pain induced by oxaliplatin treatment




Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice

It is demonstrated that chronic treatment with oxaliplatin produces neurotoxic changes in BALB/c mice, confirming that this model is a suitable tool to conduct further mechanistic studies of oxali platin-related antineoplastic activity, peripheral neurotoxicity and pain.

The contribution of satellite glial cells to chemotherapy‐induced neuropathic pain

The hypothesis that satellite glial cells in dorsal root ganglia (DRGs) are altered in chemotherapy‐induced peripheral neuropathy models and contribute to neuropathic pain is tested.

Neuropathic pain in cancer.

  • M. Fallon
  • Medicine
    British journal of anaesthesia
  • 2013
The key to management of cancer-related neuropathy is a considered assessment, remembering not to miss the opportunity of reversing the cause of the pain with appropriate oncological management.

Spinal astrocyte gap junctions contribute to oxaliplatin-induced mechanical hypersensitivity.